mRNA Influenza Vaccines Market Size, Share & Industry Analysis, By Product Type (Standalone and Combination Vaccines), By Indication (Seasonal Influenza, Pre-pandemic/Pandemic Influenza, and Broad-Spectrum/Universal Influenza), By Technology (Conventional Non-Replicating mRNA, Self-Amplifying mRNA, and Trans-Amplifying RNA), By Valency (Monovalent, Trivalent, and Quadrivalent), By Age Group (Pediatric, 18-49, 50-64, and 65+ Years), By Distribution Channel (Government Health Programs, Hospitals & Vaccination Clinics, and Retail Pharmacies & Drug Stores), and Regional Forecast, 2026-2034

The global mRNA influenza vaccines market size is valued at USD 30.0 million in 2026. The market is projected to grow from USD 150.0 million in 2027 to USD 2,192.0 million by 2034, exhibiting a CAGR of 70.99% during the forecast period.

The market is poised for robust growth in the upcoming years, along with regulatory approvals. Commercial mRNA vaccines are currently available to protect against COVID-19, with ongoing clinical development targeting other infectious diseases and cancers. Vaccine developers are increasingly exploring the technology for improving the speed, flexibility, and effectiveness of seasonal influenza immunization. Growing clinical development activity, continued investment in mRNA manufacturing infrastructure, and increasing interest in multivalent and combination respiratory vaccines are strengthening the market outlook. Overall, the market is expected to remain innovation-driven and clinical-development intensive, with growth supported by advancing late-stage vaccine candidates and increasing demand for rapidly adaptable vaccine technologies.

• For instance, in August 2026, Moderna announced that the U.S. FDA approved mFLUSIVA (mRNA-1010) for the prevention of influenza in adults aged 50 years and older, making it the first FDA-approved mRNA-based influenza vaccine.

Major players, such as Moderna, Inc., Pfizer Inc., Arcturus Therapeutics Holdings Inc., and GSK plc, are actively participating in strategic collaborations and pipeline expansion to enhance market access and strengthen their market presence.

mRNA INFLUENZA VACCINES MARKET TRENDS

Shift Toward Multi-Antigen Designs for Broader Influenza Protection to Emerge as a Key Market Trend

The global market is increasingly shifting from hemagglutinin (HA)-focused vaccine designs toward broader multi-antigen approaches targeting hemagglutinin (HA), neuraminidase (NA), and potentially other conserved influenza antigens. This shift is observed as a prominent trend as mRNA platforms provide greater flexibility to encode several antigens within a single formulation, enabling developers to generate complementary immune responses against different components of the influenza virus. Incorporating NA alongside HA may broaden protection, reduce dependence on a single antigenic target, and potentially improve protection against drifted strains, disease severity, and viral transmission. Consequently, development pipelines are increasingly emphasizing multi-antigen and broader-protection constructs, positioning antigen expansion as an important differentiation strategy for next-generation mRNA influenza vaccines. 

• For instance, in September 2026, GSK announced positive Phase II results for its investigational mRNA seasonal influenza vaccine and confirmed plans to initiate Phase III development. The candidate is designed to target both HA and NA, and generated robust immune responses against HA and NA antigens from influenza A and B strains.

MARKET DYNAMICS

Market Drivers

Download Free sample to learn more about this report.

Advancing Clinical Pipelines and Expanding Commercialization to Accelerate Market Growth

The market is expected to benefit from the maturation of late-stage clinical pipelines, along with the entry of commercial products. As investigational mRNA influenza vaccines advance through Phase II and Phase III development, the probability of regulatory approvals and commercial availability increases, directly expanding the revenue-generating market. Successful launches also provide clinical and regulatory validation of the mRNA platform beyond COVID-19, potentially encouraging additional vaccine manufacturers to invest in competing influenza programs. Increasing competition is also expected to encourage improvements in vaccine efficacy, antigen breadth, manufacturing scalability, and combination respiratory vaccine development. Consequently, the movement of candidates from clinical development toward commercialization and broader indications is expected to be an important driver of market growth. 

• For instance, in January 2026, Moderna, Inc. filed for marketing authorization for its investigational seasonal influenza vaccine, mRNA-1010, with the U.S. FDA, the European Medicines Agency (EMA), Health Canada, and the Therapeutic Goods Administration (TGA) in Australia.

Market Restraints

Premium Pricing and Tender Sensitivity May Constrain Uptake Against Established Influenza Vaccines

The adoption of mRNA influenza vaccines could be restrained by higher acquisition costs, increasing the reimbursement sensitivity of payers, governments, and institutional purchasers to reimbursement. Seasonal influenza vaccination is already served by a broad portfolio of relatively inexpensive vaccines supported by established procurement relationships and large-scale manufacturing. Consequently, mRNA vaccines may need to demonstrate sufficiently differentiated clinical benefits, including superior effectiveness, broader strain coverage, faster strain matching, or improved protection in older adults to justify a meaningful price premium. Thus, unless clinical differentiation offsets the incremental cost, premium pricing and reimbursement pressure could slow penetration of mRNA influenza vaccines.

• For instance, in August 2026, CMS published its 2026–2027 seasonal influenza vaccine payment allowances, setting the national payment allowance for Moderna’s mFLUSIVA at USD 171.21 per dose, compared with USD 122.52 for CSL Seqirus’ Fluad Trivalent and only USD 23.89 for Sanofi’s Fluzone Trivalent. Thus, mFLUSIVA carries an allowance approximately 40% above Fluad and more than seven times that of standard-dose Fluzone.

Market Opportunities

Combination Respiratory Vaccines to Expand the Addressable Seasonal Vaccination Opportunity

The development of combination respiratory vaccines integrating influenza with COVID-19 and potentially other seasonal respiratory pathogens represents a significant market opportunity. mRNA technology enables multiple antigen sequences to be incorporated within a single formulation, allowing manufacturers to develop vaccines covering more than one respiratory infection without requiring entirely separate manufacturing platforms. Combination vaccination can reduce the number of injections and vaccination visits required during the respiratory season, potentially improving patient convenience, compliance, and overall vaccine uptake. As respiratory vaccine portfolios increasingly converge, successful influenza/COVID-19 and future multi-pathogen combinations could therefore create an additional commercialization pathway for mRNA influenza platforms.

• For instance, in January 2026, Moderna stated that global regulatory submissions had advanced for mRNA-1083, its investigational influenza/COVID-19 combination vaccine, and identified the anticipated launch of the combination vaccine as an important component of its future seasonal vaccine franchise.

Market Challenges

Maintaining Consistent Protection Across Influenza Strains and Age Groups Remains Challenging

A major challenge for the mRNA influenza vaccines market growth is achieving consistent immunogenicity and clinical efficacy across multiple influenza A and B strains and across different age groups. Influenza viruses undergo continuous antigenic evolution, while immune responses can vary considerably between younger and older adults due to immunosenescence. Developers need to optimize antigen selection, dose levels, formulation, and strain balance without increasing reactogenicity. Failure to achieve comparable protection across every circulating strain can require vaccine reformulation, additional clinical studies, and delayed regulatory submissions, thereby increasing development costs and extending commercialization timelines. This challenge becomes particularly important for differentiated mRNA vaccines that must demonstrate meaningful benefits over well-established conventional influenza vaccines.

SEGMENTATION ANALYSIS

By Product Type

Greater Clinical Maturity and Lower Formulation Complexity Support Standalone Vaccine’s Leadership

Based on product type, the market is categorized into standalone mRNA influenza vaccines, combination mRNA influenza vaccines, and others.

The standalone mRNA influenza vaccines held the largest market share as they have a single-pathogen design, which reduce formulation complexity and allows developers to optimize influenza-specific antigen dose, strain balance, and immune response without potential interference from antigens targeting other respiratory viruses. Standalone vaccines can also be incorporated directly into established annual influenza vaccination schedules and evaluated against existing influenza vaccines through comparatively well-defined regulatory pathways. As a result, stronger clinical maturity and fewer formulation trade-offs have supported higher development activity and near-term commercialization potential for standalone products.

• For instance, in August 2024, Pfizer and BioNTech reported that in a separate Phase 2 trial, Pfizer evaluated trivalent influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age.

The others segment is expected to grow at a CAGR of 96.58% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Indication

Recurring Annual Vaccination and High Disease Burden Sustain Seasonal Influenza’s Dominance

Based on indication, the market is categorized into seasonal influenza, pre-pandemic/pandemic influenza, broad-spectrum/universal influenza, and others.

Seasonal influenza dominated the indication segment, as influenza epidemics recur every year and circulating strains continuously evolve, creating a recurring requirement for reformulated vaccines and annual revaccination. This recurring demand aligns particularly well with mRNA technology, which enables antigen sequences to be redesigned without fundamentally changing the underlying manufacturing platform.

• For instance, in February 2023, Moderna announced Phase 3 results for mRNA-1010, its seasonal influenza vaccine candidate, from a study enrolling 6,102 adults across multiple countries. The candidate demonstrated superior seroconversion against A/H3N2 and A/H1N1 on selected endpoints and maintained an acceptable safety profile, demonstrating the industry's substantial clinical investment in annually administered seasonal influenza vaccines.

The others segment is expected to grow at a CAGR of 105.67% over the forecast period.

By Technology

Established Clinical Development Pathways Favor Conventional Non-replicating mRNA Platforms’ Leading Position

Based on technology, the market is segmented into conventional non-replicating mRNA, self-amplifying mRNA, trans-amplifying/replicon RNA, and others.

In 2025, conventional non-replicating mRNA dominated the technology segment, driven by greater clinical-development maturity, accumulated manufacturing experience, and a more established regulatory precedent. Conventional mRNA vaccines deliver a predefined quantity of messenger RNA without intracellular RNA replication, resulting in a comparatively straightforward dose-development and manufacturing framework. Consequently, conventional modified-mRNA influenza vaccine candidates progressed into large Phase 3 programs earlier, while self-amplifying technologies remained largely in exploratory or earlier-stage development.

• For instance, in September 2022, Pfizer initiated a pivotal Phase 3 trial involving approximately 25,000 adults for its conventional modified-mRNA influenza vaccine candidate. In the same announcement, Pfizer described self-amplifying RNA as a newer technology being investigated in separate studies, demonstrating the considerably greater clinical maturity achieved by conventional modified-mRNA platforms at that stage.

The others segment is projected to grow at a 102.25% CAGR during the forecast period.

By Valency

Regulatory Approval for Trivalent Vaccines Assists in its Dominance

Based on valency, the market is segmented into monovalent, trivalent, quadrivalent, and others.

Trivalent vaccines dominated due to regulatory approval by key authorities and also due to the shift from quadrivalent vaccines following the prolonged disappearance of circulating B/Yamagata lineage viruses. Removing an antigen that no longer contributes meaningful protection simplifies vaccine composition and allows manufacturers to focus immune responses and production capacity on the three epidemiologically relevant strains: A/H1N1, A/H3N2, and B/Victoria. FDA recommended the transition to trivalent seasonal vaccines for the 2024–2025 U.S. flu season. This regulatory shift directly encouraged mRNA influenza developers to align newer candidates with three-strain compositions, increasing the segment's share.

• For instance, in June 2025, Moderna reported positive Phase 3 efficacy results for its optimized mRNA-1010 seasonal influenza vaccine, demonstrating positive relative vaccine efficacy against each of the three influenza strains represented—A/H1N1, A/H3N2, and B/Victoria.

The others segment is projected to grow at a CAGR of 105.83% during the forecast period.

By Age Group

Higher Influenza Complication Risk Concentrates mRNA Vaccine Demand Among Older Adults

Based on age group, the market is segmented into pediatric (<18 Years), 18–49 years, 50–64 years, and ≥65 years.

The ≥65 years age group segment dominates, as older adults experience disproportionately high rates of influenza-related hospitalization, complications, and mortality. At the same time, age-related immune decline can reduce the effectiveness of conventional standard-dose vaccination. This creates a greater clinical need for vaccines capable of generating stronger immune responses and encourages developers to benchmark next-generation mRNA influenza candidates.

• For instance, in September 2024, Moderna reported that an older-adult extension of its Phase 3 mRNA-1010 program met all primary immunogenicity endpoints, including superiority across all tested influenza strains compared with the licensed enhanced influenza vaccine Fluzone HD. The head-to-head evaluation against an enhanced vaccine specifically used for older populations demonstrates developers' focus on achieving clinically differentiated protection in this high-burden age group.

The pediatric (<18 years) segment is projected to grow at a CAGR of 98.80% during the forecast period.

By Distribution Channel

Convenient Community Access Positions Retail Pharmacies as the Primary Vaccination Channel

Based on distribution channel, the market is segmented into government & public health programs, hospitals & vaccination clinics, retail pharmacies & drug stores, and others.

Retail pharmacies and drug stores dominated the distribution channel segment as seasonal influenza vaccination is increasingly delivered through convenient community-based locations. These settings provide patients with extended operating hours, walk-in vaccination, widespread geographic coverage, insurance processing, and the ability to administer several seasonal vaccines during one visit. These advantages are particularly relevant for mRNA influenza vaccines targeting older adults, who already routinely receive influenza, COVID-19, RSV, and other adult vaccines through pharmacy networks.

• For instance, in August 2026, CVS Health announced nationwide availability of updated 2026–2027 influenza vaccines through CVS Pharmacy and MinuteClinic locations. Its consumer survey found that 43% of respondents planning influenza vaccination expected to receive their shot at a retail pharmacy, compared with 34% at a doctor's office.

The government & public health programs segment is projected to grow at a CAGR of 83.46% over the forecast period.

mRNA INFLUENZA VACCINES MARKET REGIONAL OUTLOOK

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America’s estimated value for 2026 is USD 27.6 million and is expected to reach USD 843.9 million in 2034. The region is anticipated to dominate the mRNA influenza vaccines market share due to early regulatory approvals and commercialization activity. Moreover, robust mRNA manufacturing infrastructure, high seasonal influenza vaccination penetration, and increasing commercialization readiness to boost market growth.

U.S. mRNA Influenza Vaccines Market

Given North America's substantial contribution and the U.S.’ dominance in the region, the U.S. market is estimated at around USD 27.4 million for 2026, accounting for roughly 91.36% of the global market.

Europe

Europe is projected to grow at a CAGR of 95.64% over the coming years and reach USD 59.2 million by 2034. Growth is supported by rapid regulatory acceptance of mRNA respiratory vaccines, established adult vaccination programs, and substantial public investment in next-generation influenza technologies, creating a favorable pathway for new products.

France mRNA Influenza Vaccines Market

France is estimated at USD 0.5 million in 2026, accounting for roughly 1.60% of the global market.

Germany mRNA Influenza Vaccines Market

Germany is projected to reach approximately USD 0.5 million in 2026, equivalent to around 1.76% of the global market.

Asia Pacific

Asia Pacific is estimated to reach USD 12.0 million in 2027 and secure the third position in the market. The regional market is expanding as countries strengthen domestic mRNA manufacturing, clinical-trial capabilities, and pandemic-preparedness infrastructure. In contrast, large populations in Australia and major Asian markets provide substantial future vaccination potential.

Japan mRNA Influenza Vaccines Market

For 2027, Japan’s market value is projected at USD 3.9 million, accounting for approximately 2.63% of the global market.

China mRNA Influenza Vaccines Market

China's market is estimated at around USD 0.8 million in 2027, accounting for approximately 0.52% of global sales.

India mRNA Influenza Vaccines Market

India’s market for 2027 is approximated at USD 0.3 million, accounting for roughly 0.18% of global revenue.

Latin America and the Middle East & Africa

Latin America is expected to witness significant growth in this market during the forecast period and is estimated to reach USD 1.8 million in 2027. Regional growth is being encouraged by technology transfer, expansion of regional vaccine manufacturing, and government-backed efforts to reduce dependence on imported vaccines, creating infrastructure that can support future mRNA influenza products. In the Middle East & Africa, the GCC is set to reach USD 0.7 million in 2027.

South Africa mRNA Influenza Vaccines Market

South Africa is projected to reach approximately USD 0.2 million in 2026, accounting for roughly 0.15% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Pipeline Advancement and Product Commercialization by Key Players Intensify Market Competition

The global mRNA influenza vaccines market has an emerging and relatively concentrated competitive structure, with companies such as Moderna, GSK, Pfizer, Arcturus Therapeutics, and BioNTech representing important commercial and clinical-development participants. The competitive landscape is primarily shaped by advanced clinical pipelines, differentiated antigen designs, proprietary mRNA delivery technologies, manufacturing capabilities, regulatory progress, and continued investments in seasonal and pandemic influenza programs.

• For instance, in April 2025, Arcturus Therapeutics announced that the U.S. FDA granted Fast Track Designation to ARCT-2304 (LUNAR-H5N1), its STARR self-amplifying mRNA vaccine candidate for pandemic influenza A H5N1. The advancement highlights growing competition through next-generation self-amplifying mRNA technologies and government-supported pandemic-preparedness programs, which could broaden the technological and product landscape of the market.

Other notable participants include CanSino Biologics, Ethris, and Sanofi, with several companies focusing on earlier-stage seasonal, pandemic, mucosal, or multivalent mRNA influenza vaccine technologies. These companies are expected to prioritize clinical advancement, strategic collaborations, government funding, broader antigen targeting, improved vaccine stability, and differentiated delivery technologies to strengthen their competitive positions during the forecast period.

List of Key mRNA Influenza Vaccines Market Companies

• Moderna, Inc. (U.S.)
• GSK plc (U.K.)
• Pfizer Inc. (U.S.)
• Arcturus Therapeutics Holdings Inc. (U.S.)
• BioNTech SE (Germany)
• SANOFI (France)
• AstraZeneca PLC (U.K.)
• CanSino Biologics Inc. (China)
• Ethris GmbH (Germany)
• CSL (Australia)
• Tiba Biotech LLC (U.S.)
• AIM Vaccine Co., Ltd. (China)
• Immorna (Hangzhou) Biotechnology Co., Ltd. (China)
• RNACure BioPharma (Shanghai) Co., Ltd. (China)
• Merck & Co., Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• September 2026: GSK plc advanced its mRNA-based seasonal influenza vaccine candidate into Phase III development following positive Phase II results. The candidate generated higher immune responses against all influenza strains evaluated compared with licensed standard- and high-dose influenza vaccines in younger and older adults, respectively.
• August 2026: Arcturus Therapeutics concluded its self-amplifying mRNA vaccine collaboration with CSL Seqirus following a joint review of the partnership. Under the collaboration, Arcturus regained global rights to its broader infectious-disease vaccine portfolio, including seasonal and pandemic influenza programs. The development provided Arcturus with greater strategic control over its mRNA influenza pipeline and future commercialization strategy.
• August 2026: Moderna, Inc. received approval from the U.S. FDA for mFLUSIVA (mRNA-1010) for the prevention of influenza in adults aged 50 years and older. The development established a new commercial category within influenza vaccination and strengthens Moderna's respiratory vaccine portfolio.
• February 2026: Ethris announced that the NOFLU consortium, comprising Ethris and six other European partners, had received an initial USD 14.6 million under a European Commission-supported tender contract. The funding aimed to support the development of Ethris' mRNA technology as a mucosal vaccine against pandemic influenza.
• December 2025: Moderna announced a partnership with CEPI under which the company would receive up to USD 54.3 million to support a pivotal Phase III trial of its mRNA-based H5 pandemic influenza vaccine, mRNA-1018. The funding is intended to accelerate development toward potential regulatory approval and strengthen preparedness against emerging pandemic influenza threats.

REPORT COVERAGE

The global mRNA influenza vaccines market report provides market size estimates and forecasts for all key segments. It evaluates the key drivers, restraints, opportunities, challenges, and emerging trends expected to influence market growth during the forecast period. The report presents a comprehensive market analysis and a detailed competitive landscape covering estimated market shares, commercial and pipeline vaccine portfolios, clinical development stages, antigen and platform strategies, regulatory progress, product launches, strategic collaborations and partnerships, manufacturing expansion initiatives, geographic presence, recent developments, and profiles of key market participants.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom-Up Approaches

Approach 1:  Company Revenue & Product-Level Sales Analysis

• Identification of approved and commercial mRNA influenza vaccine products across key countries and regions.
• Collection of company-reported product/franchise revenues, regulatory approval dates, launch timelines, geographic availability, and commercialization status.
• Assessment of manufacturer-level vaccine ASPs, annual doses supplied, procurement volumes, and channel availability.
• Allocation of influenza-specific revenues from broader respiratory/mRNA vaccine franchises wherever separately reported data is unavailable.
• Estimation of company-country revenues using dose volume × manufacturer ASP, followed by aggregation across regions.
• Commercial revenues for 2021–2025 are maintained at zero where no approved mRNA influenza vaccine sales existed, preventing premature commercialization assumptions.
• Triangulation of company revenues, regulatory approvals, product availability, and procurement activity to derive the global market estimate.

Approach 2: Target Population, Vaccination Uptake & mRNA Penetration Model

• Estimation of the eligible population by age group across major countries using national demographic datasets.
• Mapping of seasonal influenza vaccination recommendations, target populations, and vaccination coverage across adults, older adults, and other eligible populations.
• Adjustment for product label, reimbursement eligibility, geographic availability, and healthcare-access limitations.
• Estimation of the proportion of vaccinated individuals shifting from conventional influenza vaccines to mRNA-based vaccines.
• Application of conservative, base-case, and accelerated mRNA penetration assumptions depending on clinical differentiation, pricing, reimbursement, and product availability.
• Calculation of annual market revenue using eligible vaccinated population × mRNA penetration × doses per person × manufacturer ASP.
• Aggregation of country-level estimates to derive regional and global market values.

Approach 3:  Pipeline, Launch Probability & Supply-Capacity Model

• Identification of late-stage seasonal, pandemic, combination, and next-generation mRNA influenza vaccine candidates.
• Mapping of clinical stage, expected trial completion, regulatory submission, potential approval, and commercialization timelines.
• Assignment of stage-based probability of technical and regulatory success to individual pipeline candidates.
• Estimation of addressable vaccine doses following potential launch based on eligible population, competitive positioning, and expected product differentiation.
• Assessment of mRNA/LNP manufacturing, fill-finish capacity, supply agreements, government procurement, and geographic manufacturing availability.
• Calculation of probability-adjusted revenue for each pipeline asset and reconciliation against realistic adoption and production constraints.
• Exclusion or downward adjustment of programs with uncertain development timelines, discontinued partnerships, or insufficient commercialization evidence.

2. Top Down Approaches

Approach 1: Analysis of Parent Market

• Analysis of the global influenza vaccines market as the direct parent addressable market for mRNA influenza vaccines using company revenues, vaccine dose volumes, procurement data, and manufacturer ASPs.
• Estimation of the regional and country-level parent market and identification of the portion realistically addressable by mRNA vaccines based on regulatory approval, product availability, eligible age groups, and reimbursement coverage.
• Application of year-wise mRNA penetration assumptions considering clinical differentiation, pricing premium, tender competitiveness, pipeline launches, and label expansion.
• Development of conservative, base-case, and accelerated adoption scenarios to estimate substitution from egg-based, cell-based, recombinant, high-dose, and adjuvanted influenza vaccines.
• Calculation of the market using Parent Influenza Vaccine Market × Addressable Share × mRNA Penetration, followed by validation against estimated dose volumes and manufacturer ASPs.
• Maintenance of a parent-market ceiling and triangulation with company launches, regulatory approvals, procurement activity, and late-stage pipeline developments to finalize the market estimate.

3. List of Key Sources

• Company annual reports, SEC filings, investor presentations, earnings releases, and product-specific revenue disclosures.
• Company press releases, pipeline presentations, clinical-development updates, manufacturing announcements, and commercialization partnerships.
• S. FDA, EMA, Health Canada, TGA, PMDA, NMPA, and other national regulatory authorities.
• WHO, CDC, ECDC, national ministries of health, national immunization programs, and influenza surveillance systems.
• National vaccination coverage databases and seasonal influenza vaccination recommendations.
• Government tender portals, vaccine procurement contracts, reimbursement schedules, and public-health purchasing programs.
• gov, WHO ICTRP, EU Clinical Trials Information System, and national clinical-trial registries.
• Product labels, prescribing information, regulatory assessment reports, and vaccine schedules.
• Peer-reviewed clinical publications for efficacy, immunogenicity, safety, dose selection, and comparative vaccine performance.
• Company manufacturing-capacity disclosures, fill-finish arrangements, supply agreements, licensing transactions, and strategic partnerships.

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • mRNA vaccine manufacturers and biotechnology companies
  • Influenza vaccine business development and commercial strategy executives
  • Vaccine manufacturing, LNP, formulation, and fill-finish specialists
  • Regulatory affairs and market-access professionals
  • Vaccine distributors and procurement partners
  • Clinical-development and medical-affairs executives
  • Government vaccine-supply and pandemic-preparedness partners

Demand Side Interviews: 40%

• Key Respondents:
  • Infectious-disease specialists and vaccinologists
  • Primary-care physicians and geriatric-care specialists
  • Hospital and health-system vaccine procurement managers
  • Retail pharmacy and vaccination-network representatives
  • Public-health and national immunization-program authorities
  • Payers and reimbursement decision-makers
  • Influenza surveillance and epidemiology experts
  • Academic researchers involved in influenza and mRNA vaccine development